Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat.

TetraphaseÍs proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates.

Tetraphase common stock trades under the NASDAQ symbol ïTTPH.Í Tetraphase is well positioned to be a major player in the multidrug-resistant arena.